ALNY (Alnylam Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ALNY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Benjamin Cravatt | Director | A | — | — |
| 2026-06-03 | DAVID E I PYOTT | Director | MIXED | — | — |
| 2026-05-22 | Stuart A Arbuckle | Director | A | — | — |
| 2026-05-22 | Dennis A Ausiello | Director | A | — | — |
| 2026-05-22 | OLIVIER BRANDICOURT | Director | A | — | — |
| 2026-05-22 | MARGARET A HAMBURG | Director | A | — | — |
| 2026-05-22 | PETER N KELLOGG | Director | A | — | — |
| 2026-05-22 | DAVID E I PYOTT | Director | A | — | — |
| 2026-05-22 | Colleen F Reitan | Director | A | — | — |
| 2026-05-22 | AMY W SCHULMAN | Director | A | — | — |
| 2026-05-22 | Charles Elliott Sigal | Director | A | — | — |
| 2026-05-14 | AMY W SCHULMAN | Director | M | — | — |
| 2026-04-07 | Melissa McLaughlin | Chief Human Resources Officer | Sell | — | — |
| 2026-03-06 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sell | — | — |
| 2026-03-06 | Tolga Tanguler | EVP, Chief Commercial Officer | Sell | — | — |
| 2026-03-06 | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sell | — | — |
| 2026-03-06 | Yvonne Greenstreet | Chief Executive Officer | Sell | — | — |
| 2026-03-06 | Pushkal Garg | EVP Chief R&D | Sell | — | — |
| 2026-03-04 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2026-03-04 | BRYAN SUPRAN | EVP, CLO and Secretary | A | — | — |
| 2026-03-04 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-03-04 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | — |
| 2026-03-04 | Pushkal Garg | EVP Chief R&D | MIXED | — | — |
| 2026-03-04 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | Pushkal Garg | EVP Chief R&D | MIXED | — | — |
| 2026-03-02 | Tolga Tanguler | EVP, Chief Commercial Officer | M | — | — |
| 2026-03-02 | Jeffrey V. Poulton | EVP, Chief Financial Officer | M | — | — |
| 2026-03-02 | Yvonne Greenstreet | Chief Executive Officer | M | — | — |
| 2026-02-25 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | A | — | — |
| 2026-02-17 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-02-17 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | — |
| 2026-02-17 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-02-17 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2026-02-17 | Pushkal Garg | EVP Chief R&D | MIXED | — | — |
| 2026-01-14 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | — |
| 2026-01-14 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-01-14 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-01-14 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2026-01-14 | Pushkal Garg | EVP Chief R&D | MIXED | — | — |
| 2026-01-07 | Stuart A Arbuckle | Director | A | — | — |
| 2025-12-01 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2025-11-19 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | — |
| 2025-11-14 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2025-10-03 | Pushkal Garg | EVP Chief R&D | MIXED | — | — |
| 2025-10-03 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | — |
| 2025-10-03 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | — | — |
| 2025-10-03 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | — |
| 2025-10-03 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | — | — |
| 2025-10-03 | BRYAN SUPRAN | EVP, CLO and Secretary | A | — | — |
| 2025-09-11 | Colleen F Reitan | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,554,134 | — |
| — | 10%+ Owner | 5,602,898 | — |
| — | 10%+ Owner | 4,051,002 | — |
| — | Director | 316,996 | — |
| — | Director | 266,899 | — |
| — | Chief Executive Officer | 231,115 | — |
| — | Chief Executive Officer | 96,712 | — |
| — | President | 68,588 | — |
| — | EVP, Chief Financial Officer | 64,107 | — |
| — | EVP, Chief Commercial Officer | 36,398 | — |
| — | Director | 32,391 | — |
| — | VP of Finance and Treasurer | 26,165 | — |
| — | Director | 25,000 | — |
| — | President | 24,706 | — |
| — | Director | 24,049 | — |
| — | SVP, Chief Business Officer | 22,671 | — |
| — | CSO & EVP, Head of Research | 21,821 | — |
| — | EVP Chief R&D | 20,874 | — |
| — | Director | 20,804 | — |
| — | EVP, CLO and Secretary | 14,565 | — |
| — | Chief Human Resources Officer | 11,729 | — |
| — | Director | 10,799 | — |
| — | Director | 8,991 | — |
| — | EVP, CLO and Secretary | 8,002 | — |
| — | EVP, Chief Legal Officer | 5,566 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALNY quote page; the site-wide leaderboard is on the insider transactions hub.